메뉴 건너뛰기




Volumn 2, Issue 2, 2002, Pages 155-185

Design of selectively activated anticancer prodrugs: Elimination and cyclization strategies

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; ACIVICIN; ACROLEIN; ACROLEIN DERIVATIVE; AMIDE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BETA GLUCURONIDASE; CARBAMIC ACID DERIVATIVE; CARBONIC ACID; CHLORMETHINE DERIVATIVE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACTINOMYCIN; DAUNORUBICIN; DAUNORUBICIN DERIVATIVE; DICHLORODIETHYLAMINE; DOXORUBICIN DERIVATIVE; MITOMYCIN C; N (4 BETA GLUCURONYL 3 NITROBENZYLOXYCARBONYL)DOXORUBICIN; NAPHTHOQUINONE; OXAZOLIDINONE DERIVATIVE; PHOSPHORAMIDE MUSTARD; PLASMIN; PRODRUG; TALLIMUSTINE; TUMOR ANTIGEN; UNINDEXED DRUG;

EID: 0036080057     PISSN: 15680118     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568011023354173     Document Type: Review
Times cited : (63)

References (154)
  • 62
    • 84872261951 scopus 로고
    • Eli Lilly & Co., Hybritech Inc., European Patent Application, 0382 411A2
    • (1990)
  • 66
    • 84872264568 scopus 로고
    • Bristol-Myers Co., Eur. Pat. Appl. 0 484 870 A2
    • (1992)
  • 113
    • 84872275149 scopus 로고
    • National Toxicology Program "Toxicology and Carcinogenesis Studies of Coumarins"; U.S. Department of Health and Human Services: Public Health Service and National Institutes of Health
    • (1993)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.